Carmen Cristescu *
* Dr. Carmen Cristescu, şef de lucrări, disciplina de Farmacologie, UMF Timişoara
Abstract
No other class of antitumor agents has gained ground in the oncologic dai ly practice as fast as the anthracyclines. Usual ly prescribed as part of polichimiotherapy schedules, anthracyclines bring a valuable approach to a wide range of malign states such as: Hodgking and non-Hodgkin lymphomas, breast, ovarian, lung cancer, malign tumors of gastrointestinal tract. Currently, new anthracycl ine compouds (such as epirubicine, idarubicine) play a major role in neoplasias therapy due to their antitumoral effect, equivalent to that one of doxorubicin and to their improved tolerance.